An article in today's New York Times looks at Genocea, a biotech startup led by Harvard molecular geneticist Darren Higgins. The company aims to design inexpensive vaccines by triggering proteins to mimick a healthy immune response to resist attack by an invader like TB.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.